|
Variables associated with overall survival in the univariate analysis |
|||
| Variables |
No. of patients |
Median survival (months ± SD) |
p-value |
|
|
|||
| Overall |
44 (100%) |
11.5 ± 1.8 |
|
|
|
|||
| No cirrhosis/Child A |
30 (68%) |
13.7 ± 1.7 |
|
| Child B |
9 (21%) |
6.3 ± 2.8 |
p = 0.01 |
| Child C |
5 (11%) |
0.4 ± 0.1 |
|
|
|
|||
| Okuda stage I |
13 (29%) |
15.7 ± 6.4 |
|
| Okuda stage II |
28 (64%) |
10.4 ± 1.7 |
p < 0.001 |
| Okuda stage III |
3 (7%) |
0.4 ± 0.0 |
|
|
|
|||
| CLIP 0 |
2 |
37.1* |
|
| CLIP 1 |
10 |
13.7 ± 2.7 |
|
| CLIP 2 |
15 |
13.6 ± 2.7 |
p < 0.001 |
| CLIP 3 |
10 |
8.1 ± 1.6 |
|
| CLIP 4–6 |
7 |
0.5 ± 0.1 |
|
|
|
|||
| AFP < 400 ng/ml |
29 (66%) |
16.2 ± 3.5 |
p < 0.001 |
| AFP > 400 ng/ml |
15 (34%) |
6.3 ± 2.6 |
|
|
|
|||
| thymostimulin only |
19 (43%) |
10.1 ± 4.7 |
p = 0.1 |
| additional therapy modalities |
25 (57%) |
13.7 ± 2.1 |
|
|
|
|||
| no vascular invasion |
30 (68%) |
11.5 ± 2.2 |
p = 0.3 |
| with vascular invasion |
14 (32%) |
10.8 ± 2.8 |
|
|
|
|||
| no extrahepatic metastases |
35 (79%) |
13 ± 1.7 |
p = 0.1 |
| with extrahepatic metastases |
9 (21%) |
8 ± 7.5 |
|
|
* SD not applicable due to low patient number | |||
Dollinger et al. BMC Cancer 2008 8:72 doi:10.1186/1471-2407-8-72 |
|||